Helping investors discover, understand, and stay up-to-date on investment opportunities within the Psychedelic industry.
Performance of psychedelic public companies this past week.
Tryp Therapeutics ($TRYP | $TRYPF) announced that the first patient has been dosed in their Phase II clinical trial. The study is focused on the safety and preliminary efficacy of psilocybin-assisted therapy among patients with binge eating disorder. Press Release
Optimi Health ($OPTI | $OPTHF) opened Canada's largest GMP-grade licensed psilocybin cultivation facility. Optimi’s facility will be focused on the production of natural GMP psilocybin for use in clinical trials and individuals granted access by Health Canada. Press Release
Field Trip Health ($FTRP) announced their intentions to separate the Field Trip Discovery and Field Trip Health division into two independent public companies. The transaction will create two distinct emerging leaders in the psychedelics industry, one providing personalized care and the other developing next generation psychedelic therapies. Press Release
Wellbeing Digital Sciences (($MEDI | $KONEF) announced that their subsidiary, IRP Health, has been approved as part of the Chronic Pain Centre of Excellence for Canadian veterans. Additionally, IRP Health’s clinic in Ottawa has been approved by Veterans Affair Canada for their multidisciplinary Reactivation-branded therapy program. Press Release
Filament Health ($FH | $FLHLF) has been issued a fourth patent for the extraction and standardization of natural psilocybin and associated psychedelic compounds. Filament's latest patent describes essential technology for transforming variable psychedelic raw materials into pharmaceutical-grade, standardized drug candidates. Press Release
PsyBio Therapeutics ($PSYB | $PSYBF) submitted an application to convert existing provisional patents to full patents. The submission covers major markets including North America, Europe, Asia-Pacific, and Africa. Press Release
PharmaTher Holdings ($PHRM | $PHRRF) provided operational updates. Highlights included a research collaboration with Revive Therapeutics, orphan drug designation for ketamine to treat status epilepticus, and a patent for a formulation of FDA-approved ketamine and betaine anhydrous KETABET. Press Release
Albert Labs International ($ABRT) appointed Professor Robert Britton, a Natural Product Chemist, and renowned toxicologist and pharmacologist, Dr. Dinis-Oliveira, to their Scientific Advisory Board. Press Release